Immunoprotein is a protein with immunological activity. When in an unhealthy state, they display an abnormal increase in their blood concentration, thus acting as a potential indicator for disease diagnosis. The market of global immunoprotein diagnostic testing is on an upswing owing to a large pool of geriatrics and high occurrence of chronic diseases.

The incidence of various infectious diseases is multiplying and a large section of the population in developing economies is suffering due to unhygienic conditions and illiteracy. Many are reportedly succumbing to malaria and cancer, hence early diagnosis is high in demand. This is where immunoprotein diagnostic testing comes in handy. As new and innovative technologies are being continuously introduced in the market, the shelf life of the products is shrinking, thereby acting as a hindrance for market players.

According to Transparency Market Research, the global immunoprotein diagnostic testing market is estimated to reach US$15.3 bn by 2019.

Expensive Radioimmunoassay to Trail Other Assay Market Segments

Based on technology, chemiluminescence assay is a rapidly growing segment and growth of this market can be attributed to a wide scope of application, increased sensitivity, and ease of use. Fuelled by the development of multiple ELISA technologies, the ELISA market is expected to grow in a significant manner. On the contrary, the radioimmunoassay segment is expected to lose its footing in the market due to government restrictions on the use of radioactive substances and high cost of assay equipment and safety devices. In addition, the segment will experience a downfall as better and safer technologies such as chemiluminescence assay, ELISA, and immunofluorescence assay will replace radioimmunoassay soon. Immunofluorescence and immunoturbidity assay segments are expected to grow at a modest CAGR of about 5% during the forecast period.

The application of immunoprotein diagnostic testing can be found in infectious diseases, oncology testing, endocrine testing, toxicology testing, allergy testing, and autoimmune disease testing. Oncology testing is projected to account for a large market share in the forecast period. Commoditization of products, growing demand for quick, accurate, and preventive healthcare, especially in emerging economies, technological developments, expansions in the field of immunochromatography, and strengthening network of distributors at a global level will contribute to the market growth – generating maximum revenue of US$4,943.0 mn by 2019.

High Prevalence of Chronic Diseases to Push Sales in the U.S.

The immunoprotein diagnostic testing market is geographically segmented into North America, Europe, Asia Pacific, and Rest of the World. High incidence of chronic and infectious diseases, shift to POC rapid diagnostic tests, laboratory automation, and increased FDA approval for new products are some of the key factors that have led North America to dominate the said market. According to the report, this region is projected to continue enjoying its top position in the forecast period as well.

Developing economies of Asia Pacific are also expected to contribute to the market growth in the years to come. Better healthcare facilities, increase in disposable income, improving literacy rate, and growing awareness about major infectious and chronic diseases are few of the factors that are fuelling the demand for immunoprotein diagnostic testing in this region.

Immunoprotein diagnostic testing market is continuously fueled with innovative technologies which are shrinking product life cycle and also expanding the boundaries of market. These innovations have also increased the scope of application in various medical fields. The market for immunoprotein diagnostic testing has been segmented according to various immunoproteins, which help in immune response modulation. These include immunoglobulins, complement system proteins, C-reactive protein (CRP), haptoglobin, prealbumin and free light chains (FLC) of immunoglobulins. Each of these proteins plays a characteristic role in the immune response, and hence the level of these immunoproteins has been considered as an indication of diseased state.

Immunoprotein diagnostic testing market has been studied from the perspective of technology platforms such as enzyme linked immunosorbent assay (ELISA), chemiluminescence assay, immunofluorescence assay, immunoturbidity assay, radioimmunoassay, and immunoprotein electrophoresis. Enzyme linked immunosorbent assay is the most widely used technique in the diagnosis of various diseases globally. On the other hand, the market for chemiluminescence assay technology was found to be fastest growing segment owing to broad applications in disease diagnosis, drug testing, oncology and various others.

Further, immunoprotein diagnostic testing market has also been segmented according to application in diagnosis of various diseases. These include infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and autoimmune disease testing. Oncology segment is growing rapidly owing to increased disease prevalence and high cost of assay kits. Geographically, the immunoprotein diagnostic testing market has been segmented into four major regions, namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). Each of these four geographies is further segmented according to assay technologies. Immunoprotein diagnostic testing market report also details market attractiveness analysis for these geographies. The analysis is based on various factors such as current stage of life cycle, market size, customer base, market competition, and annual growth rate.

Immunoprotein diagnostic testing market is subjected to various micro as well as macro economic factors. The impact of these factors has been studied to forecast the future trends. The report also provides detailed Porter’s five forces analysis of the immunoprotein diagnostic testing market. Based on in depth analysis and comprehensive market study, key factors driving and restraining the market have been discussed. Moreover lucrative opportunities and relevant recommendations for sustainable growth in the immunoprotein diagnostic testing market also have been suggested. Each of the market segments has been analyzed on the basis of current and future market size for the period 2011 to 2019, in terms of revenue (USD million), considering 2011 and 2012 as the base years. The compounded annual growth rate (% CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. An exhaustive heat map analysis of key market players such as Abbott Laboratories, Abcam PLC, Diasorin, Enzo Life Sciences, Randox Laboratories, Roche, Siemens, The Binding Site, and Thermo Fisher Scientific is provided in this report. Each of these key market players are profiled in the report considering parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The research methodology was based on primary as well as secondary research. Interviews and discussions with a wide range of key industry participants and opinion leaders revealed real time market scenario. This primary research represented the bulk of the research efforts, which was further supplemented by extensive secondary research. A review of key players’ product literature, annual reports, and press releases supports the market forecast analysis. The 99 pages immunoprotein diagnostic testing market reports described various market dynamics in 30 figures and charts and 9 tables.